List of works - Daniel B Costa

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

scientific article published in September 2007

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

scientific article

A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome.

scientific article published on 15 February 2006

A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred.

scientific article published on 8 September 2005

ALK inhibitors: plateauing systemic and intracranial activity?

scientific article published on 10 March 2016

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

scientific article

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

scientific article published on July 2009

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

scientific article published in March 2012

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

scientific article published on 04 September 2012

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

scientific article

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

scientific article

Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth

scientific article published on 15 March 2016

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

scientific article

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

scientific article

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

scientific article

C/EBPα mutations in lung cancer

scientific article published on 12 June 2006

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.

scientific article

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

scientific article

Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

scientific article published in July 2006

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.

scientific article published on June 2011

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

scientific article published on 26 January 2015

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

scientific article

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

scientific article

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

scientific article

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

scientific article

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib ⬇️

scientific article published on October 28, 2010

Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature.

scientific article

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

scientific article

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

scientific article published on 14 October 2013

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

scientific article

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.

scientific article

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

scientific article

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

scientific article

Erlotinib-associated alopecia in a lung cancer patient.

scientific article

Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.

scientific article published in March 2013

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells

scientific article published on 15 October 2006

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

scientific article

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations ⬇️

scientific article published on December 27, 2012

Gefitinib plus docetaxel in non-small-cell lung cancer

scientific article

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities ⬇️

scientific article published on May 1, 2011

Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.

scientific article

Hyperglycemia and biliary tract adenocarcinoma.

scientific article published in February 2006

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

scientific article

Identification of Somatic Genomic Alterations in Circulating Tumors Cells: Another Step Forward in Non–Small-Cell Lung Cancer? ⬇️

scientific article published on May 13, 2013

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

scientific article published on 01 July 2006

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

scientific article

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma ⬇️

scientific article published on January 1, 2011

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma

scientific article published on February 2016

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

scientific article

Management and future directions in non-small cell lung cancer with known activating mutations

scientific article published on January 2014

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

scientific article

Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer.

scientific article published in October 2005

Molecular testing in lung cancer: the time is now.

scientific article published on September 2010

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

scientific article

Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

scientific article published on 22 November 2011

Pneumococcemia as the presenting feature of multiple myeloma

scientific article published on 01 November 2004

Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population.

scientific article published in August 2009

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

scientific article published on 3 July 2007

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

scientific article

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

scientific article published on 07 March 2016

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

scientific article published on 18 July 2011

Recurrent Infections in Multiple Myeloma

scientific article published on 01 April 2006

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

scientific article

Safety of Cupping During Bevacizumab Therapy ⬇️

scientific article published on February 4, 2013

Serum concentrations of Erlotinib at a dose of 25 mg daily.

scientific article

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

scientific article published on 07 August 2013

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

scientific article

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

scientific article published on 28 January 2014

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review

scientific article published on 26 March 2015

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations ⬇️

scientific article published on June 25, 2012

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer

scientific article published on 05 August 2020

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

scientific article published on 04 March 2016

Three-year survival in metastatic non-small cell lung cancer treated with gefitinib

scientific article published on 24 May 2006

Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19

scientific article published on 24 July 2020

To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress

scientific article published on 13 June 2007

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung

scientific article

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

scientific article

β-catenin contributes to lung tumor development induced by EGFR mutations

scientific article

List of works by Daniel B Costa

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome.

A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred.

ALK inhibitors: plateauing systemic and intracranial activity?

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

C/EBPα mutations in lung cancer

CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma.

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib ⬇️

Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients.

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Erlotinib-associated alopecia in a lung cancer patient.

Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations ⬇️

Gefitinib plus docetaxel in non-small-cell lung cancer

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities ⬇️

Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.

Hyperglycemia and biliary tract adenocarcinoma.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

Identification of Somatic Genomic Alterations in Circulating Tumors Cells: Another Step Forward in Non–Small-Cell Lung Cancer? ⬇️

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma ⬇️

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma

Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis

Management and future directions in non-small cell lung cancer with known activating mutations

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer.

Molecular testing in lung cancer: the time is now.

More than just an oncogene translocation and a kinase inhibitor: Kevin's story.

Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

Pneumococcemia as the presenting feature of multiple myeloma

Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population.

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Recurrent Infections in Multiple Myeloma

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Safety of Cupping During Bevacizumab Therapy ⬇️

Serum concentrations of Erlotinib at a dose of 25 mg daily.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations ⬇️

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

Three-year survival in metastatic non-small cell lung cancer treated with gefitinib

Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19

To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

β-catenin contributes to lung tumor development induced by EGFR mutations